FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
FiercePharma4d
Roche burnishes breast cancer portfolio with FDA approval for Itovebi, a threat to Novartis and AZ
As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Approval is based on Phase III INAVO120 results, showing the Itovebiâ„¢ (inavolisib)-based regimen more than doubled ...
Roche gets FDA approval for Itovebi combo therapy for breast cancer
Roche (RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of breast ...
Cure Today4d
FDA Approves Itovebi Combo for Some With Advanced Breast Cancer
The Food and Drug Administration (FDA) has approved Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant ...
Managed Healthcare Executive4d
FDA Approves Itovebi for Metastatic Breast Cancer
Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...
pharmaphorum4d
Roche gets FDA green light for breast cancer drug Itovebi
Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...
GlobalData on MSN4d
Roche wins first-line approval for PI3K inhibitor combo in breast cancer
The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...
Cancer Therapy Advisor4d
Itovebi Approved for Advanced Breast Cancer With PIK3CA Mutations
The FDA has approved Itovebi in combination with palbociclib and fulvestrant to treat certain patients with PIK3CA-mutant breast cancer.
Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting
RHHBY obtains FDA approval for Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
The Pharma Letter4d
FDA approves Genentech’s Itovebi for PIK3CA-mutated mBC
The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...
WebMD22h
New Drug Approved for Common Type of Breast Cancer Recurrence
A new breast cancer drug has received quick federal approval after a clinical trial showed it could more than double the time before a common type of breast cancer recurrence worsens.